JP7779738B2 - 自己免疫疾患を治療するための抗ｃｄ１９抗体の使用 - Google Patents

自己免疫疾患を治療するための抗ｃｄ１９抗体の使用

Info

Publication number
JP7779738B2
JP7779738B2 JP2021563213A JP2021563213A JP7779738B2 JP 7779738 B2 JP7779738 B2 JP 7779738B2 JP 2021563213 A JP2021563213 A JP 2021563213A JP 2021563213 A JP2021563213 A JP 2021563213A JP 7779738 B2 JP7779738 B2 JP 7779738B2
Authority
JP
Japan
Prior art keywords
nmosd
patient
months
vib551
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021563213A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022529743A (ja
JPWO2020219743A5 (https=
JP2022529743A5 (https=
Inventor
エリエゼル カッツ
ヨルン ドラッパ
キャサリーン マッキーバー
Original Assignee
ビエラ バイオ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ビエラ バイオ インコーポレイテッド filed Critical ビエラ バイオ インコーポレイテッド
Publication of JP2022529743A publication Critical patent/JP2022529743A/ja
Publication of JPWO2020219743A5 publication Critical patent/JPWO2020219743A5/ja
Publication of JP2022529743A5 publication Critical patent/JP2022529743A5/ja
Priority to JP2025120173A priority Critical patent/JP2025157413A/ja
Application granted granted Critical
Publication of JP7779738B2 publication Critical patent/JP7779738B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021563213A 2019-04-24 2020-04-23 自己免疫疾患を治療するための抗ｃｄ１９抗体の使用 Active JP7779738B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025120173A JP2025157413A (ja) 2019-04-24 2025-07-17 自己免疫疾患を治療するための抗ｃｄ１９抗体の使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962838093P 2019-04-24 2019-04-24
US62/838,093 2019-04-24
US201962843096P 2019-05-03 2019-05-03
US62/843,096 2019-05-03
US201962858495P 2019-06-07 2019-06-07
US62/858,495 2019-06-07
PCT/US2020/029613 WO2020219743A2 (en) 2019-04-24 2020-04-23 Use of an anti-cd19 antibody to treat autoimmune disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025120173A Division JP2025157413A (ja) 2019-04-24 2025-07-17 自己免疫疾患を治療するための抗ｃｄ１９抗体の使用

Publications (4)

Publication Number Publication Date
JP2022529743A JP2022529743A (ja) 2022-06-23
JPWO2020219743A5 JPWO2020219743A5 (https=) 2023-09-14
JP2022529743A5 JP2022529743A5 (https=) 2023-09-14
JP7779738B2 true JP7779738B2 (ja) 2025-12-03

Family

ID=72940915

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021563213A Active JP7779738B2 (ja) 2019-04-24 2020-04-23 自己免疫疾患を治療するための抗ｃｄ１９抗体の使用
JP2025120173A Pending JP2025157413A (ja) 2019-04-24 2025-07-17 自己免疫疾患を治療するための抗ｃｄ１９抗体の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025120173A Pending JP2025157413A (ja) 2019-04-24 2025-07-17 自己免疫疾患を治療するための抗ｃｄ１９抗体の使用

Country Status (12)

Country Link
US (1) US20220204617A1 (https=)
EP (1) EP3959241A4 (https=)
JP (2) JP7779738B2 (https=)
KR (1) KR20220004113A (https=)
CN (1) CN113939532A (https=)
AU (1) AU2020263418A1 (https=)
BR (1) BR112021020924A2 (https=)
CA (1) CA3136487A1 (https=)
IL (1) IL287385A (https=)
MX (1) MX2021012870A (https=)
SG (1) SG11202111429UA (https=)
WO (1) WO2020219743A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3809260A1 (de) * 2019-10-18 2021-04-21 Siemens Healthcare GmbH System und verfahren zur administration von bildgebenden geräten
JP2023534916A (ja) * 2020-06-30 2023-08-15 ビエラ バイオ インコーポレイテッド 視神経脊髄炎スペクトラム障害を治療する方法
JP2023549075A (ja) * 2020-10-29 2023-11-22 ビエラ バイオ インコーポレイテッド 自己免疫疾患を治療するための抗ｃｄ１９抗体の使用
IL308296A (en) * 2021-05-07 2024-01-01 Viela Bio Inc Use of anti-CD19 antibody to treat myasthenia gravis
KR20250044695A (ko) 2022-07-27 2025-04-01 비엘라 바이오, 인크. 이네빌리주맙 및 지속적인 b-세포 고갈을 위한 이의 사용 방법
WO2024155810A1 (en) * 2023-01-20 2024-07-25 Viela Bio, Inc. Anti-cd19 binding agents for the treatment and prevention of immune mediated necrotizing myopathy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010502232A (ja) 2006-09-08 2010-01-28 メディミューン，エルエルシー ヒト化抗ｃｄ１９抗体ならびに癌、移植および自己免疫疾患の治療におけるその使用
JP2012519712A (ja) 2009-03-06 2012-08-30 メディミューン，エルエルシー ヒト化抗ｃｄ１９抗体製剤
JP2015515456A (ja) 2012-03-12 2015-05-28 メディミューン，エルエルシー 抗ｃｄ１９抗体による多発性硬化症の治療

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2066349T1 (sl) * 2006-09-08 2012-08-31 Medimmune Llc Humanizirana anti-cd19 protitelesa in njihova uporaba v zdravljenju tumorjev, transplantacijah in avtoimunih boleznih
GB201401465D0 (en) * 2014-01-29 2014-03-12 Roach Arthur H Use of cladribine for treating autoimmune inflammatory disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010502232A (ja) 2006-09-08 2010-01-28 メディミューン，エルエルシー ヒト化抗ｃｄ１９抗体ならびに癌、移植および自己免疫疾患の治療におけるその使用
JP2012519712A (ja) 2009-03-06 2012-08-30 メディミューン，エルエルシー ヒト化抗ｃｄ１９抗体製剤
JP2015515456A (ja) 2012-03-12 2015-05-28 メディミューン，エルエルシー 抗ｃｄ１９抗体による多発性硬化症の治療

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J Neurol Sci.，2016年，Vol.366，p.1-20，doi: 10.1016/j.jns.2016.04.039
JOURNAL OF NEUROLOGICAL SCIENCES，2017年，Vol.381，p.8（No.25)，DOI: 10.1016/J.JNS.2017.08.050
M. Hoffman，lnebilizumab Gets Breakthrough Designation for Neuromyelitis Optica Spectrum Disorder，Neurology Live，2019年04月19日，URL:https://www.neurologylive.com/view/inebilizumab-breakthrough-designation-neuromyelitis-optica-spectrum-disorder

Also Published As

Publication number Publication date
MX2021012870A (es) 2022-01-18
WO2020219743A2 (en) 2020-10-29
US20220204617A1 (en) 2022-06-30
EP3959241A4 (en) 2023-01-25
JP2022529743A (ja) 2022-06-23
IL287385A (en) 2021-12-01
EP3959241A2 (en) 2022-03-02
SG11202111429UA (en) 2021-11-29
BR112021020924A2 (pt) 2022-04-19
JP2025157413A (ja) 2025-10-15
CA3136487A1 (en) 2020-10-29
CN113939532A (zh) 2022-01-14
KR20220004113A (ko) 2022-01-11
AU2020263418A1 (en) 2021-11-11
WO2020219743A3 (en) 2020-12-10

Similar Documents

Publication Publication Date Title
JP7779738B2 (ja) 自己免疫疾患を治療するための抗ｃｄ１９抗体の使用
Feng et al. Pembrolizumab-induced encephalopathy: a review of neurological toxicities with immune checkpoint inhibitors
Kahn et al. Favorable response to high-dose infliximab for refractory childhood uveitis
RU2728710C2 (ru) Способы лечения нерентгенографического аксиального спондилоартрита, используя антагонисты интерлейкина-17 (il-17)
US20250034265A1 (en) Treatment of a demyelinating disease of the central nervous system (cns) with satralizumab
US20260103532A1 (en) Pharmaceutical compositions of humanized anti-cd40 antibodies and uses thereof
US20210284741A1 (en) Methods for the treatment of thyroid eye disease
JP2017528465A (ja) 乾癬性関節炎患者における構造的損傷の進行を阻害するためのｉｌ−１７アンタゴニストの使用
Rocco et al. Bortezomib treatment for refractory nontuberculous mycobacterial infection in the setting of interferon gamma autoantibodies
JP2024069373A (ja) 視神経脊髄炎の処置のためのエクリズマブ
KR20220062025A (ko) 요법 교체에 의한 rms의 치료
US20240270842A1 (en) Use of an anti-cd19 antibody to treat myasthenia gravis
CN116322765A (zh) 用于用奥瑞珠单抗治疗多发性硬化症的方法
EA052907B1 (ru) Применение антитела к cd19 для лечения миастении гравис
TW202330022A (zh) 抗ｃｄ１９抗體治療重症肌無力之用途
RU2849464C1 (ru) Лечение rms путем смены терапии
KR20250075690A (ko) 비활성 또는 만성 갑상선 눈 질환의 치료 방법
Wiśniewska et al. Exploring treatment approaches for Neuromyelitis Optica Spectrum Disorders (NMOSD)
WO2025101427A1 (en) Use of an immunoconjugate for the treatment of endometrial cancer
Deodhar A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY OF THE EFFICACY AND SAFETY OF TOFACITINIB IN SUBJECTS WITH ACTIVE ANKYLOSING SPONDYLITIS (AS)
Katayama et al. SAT0166 Which biologic agent is most suitable for an extended-interval treatment for rheumatoid arthritis? results from a multicenter study
Eckstein Induction therapy
Nurmohamed Marieke M ter Wee, Debby den Uyl, Maarten Boers, Pit Kerstens, Mike Nurmohamed, Dirkjan van Schaardenburg, Alexandre E Voskuyl, Willem F Lems
Opris et al. AB0422 Serum Drug Level and Anti-Citrullinated Peptide Antibodies as Biomarkers That Predict Eular Response in Rheumatoid Arthritis-A New Step to Personalized Medicine
Moretz Drug Class Review with New Drug Evaluation: Biologics for Autoimmune Disorders-Neuromyelitis Optica Spectrum Disorder

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230421

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230421

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230905

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20230905

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240411

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241010

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250717

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251023

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251120

R150 Certificate of patent or registration of utility model

Ref document number: 7779738

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150